Acute Inc. v. ECI Pharmaceuticals LLC

CourtUnited States Bankruptcy Court, S.D. Florida.
DecidedMay 21, 2025
Docket25-01048
StatusUnknown

This text of Acute Inc. v. ECI Pharmaceuticals LLC (Acute Inc. v. ECI Pharmaceuticals LLC) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. Florida. primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Acute Inc. v. ECI Pharmaceuticals LLC, (Fla. 2025).

Opinion

ores, OS aR’ if * □ iD 8 Ss 74 □□□ a Ways 6 Me AIK □□ □□ AR Sa pisruct OF oe ORDERED in the Southern District of Florida on May 21, 2025.

Scott M. Grossman, Judge United States Bankruptcy Court

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF FLORIDA FORT LAUDERDALE DIVISION In re: ECI PHARMACEUTICALS LLC, Case No. 24-14430-SMG Debtor. Chapter 11 (Subchapter V) ef In re: Case No. 24-14431-SMG BIORAMO, LLC, Chapter 11 (Subchapter V) Debtor. Jointly administered ef ACUTE INC., GENETIC NETWORKS LLC, and DR. RAJU’S PHARMA SOLUTIONS, LLC, Plaintiffs, V. Adv. No. 25-01048-SMG ECI PHARMACEUTICALS LLC, BIORAMO, LLC, ECI LIQUIDATING TRUST, and KATIE GOODMAN, as Liquidating Trustee, Defendants. ef

ORDER (I) DENYING MOTION TO DISMISS FOR LACK OF SUBJECT MATTER JURISDICTION, BUT (II) STAYING ADVERSARY PROCEEDING PENDING OUTCOME OF APPEAL Bankruptcy Code section 1144 permits a party in interest to request the court revoke a chapter 11 confirmation order if it was procured by fraud. That request must be brought within 180 days of the confirmation order’s entry. The plaintiffs here timely filed a complaint seeking that relief. But one of those plaintiffs, Acute, Inc., had previously appealed the confirmation order on another basis – that it improperly approved nonconsensual third-party releases. Because that appeal is still pending, the defendants seek to dismiss this adversary proceeding for lack of subject matter jurisdiction based on the “divestiture rule.”

As the Supreme Court stated in Griggs v. Provident Consumer Discount Co., “a notice of appeal is an event of jurisdictional significance—it confers jurisdiction on the court of appeals and divests the district court of its control over those aspects of the case involved in the appeal.”1 But 28 U.S.C. §§ 1334(b) and 157(a), together with the District Court’s general order of reference, plainly grant this Court subject matter jurisdiction over the timely-filed complaint. The Court must therefore reconcile the

judicially created divestiture rule with the Congressional grant of jurisdiction. For the reasons discussed below, the Court concludes that the defendants overstate the jurisdictional nature of the divestiture rule, at least insofar as it pertains to a bankruptcy court’s authority to adjudicate certain matters when there is a pending appeal. The divestiture rule is not truly jurisdictional, and this Court

1 459 U.S. 56, 58 (1982). does not lack subject matter jurisdiction over this adversary proceeding. But, due to the current posture of this bankruptcy case – and as a matter of comity and deference to the District Court with respect to the pending appeal – under the authority of 11

U.S.C. § 105(a) and Federal Rule of Bankruptcy Procedure 7016(b)(3), the Court will stay this adversary proceeding pending the resolution of the appeal. I. BACKGROUND. Debtors ECI Pharmaceuticals LLC and BioRamo LLC filed voluntary petitions for relief under chapter 11 of the Bankruptcy Code on May 3, 2024.2 On August 30, 2024, the Court approved a sale of substantially all of the debtors’ assets to Acute.3 The sale still has not closed, and Acute has appealed the sale order.4 That appeal is

still pending.5 On October 22, 2024, the Court then held a hearing to consider confirmation of the debtors’ joint chapter 11 plan of liquidation.6 No written objections to confirmation were filed, and no party objected at the confirmation hearing. In fact, Acute did not even appear at the confirmation hearing. On October 24, 2024, the Court entered an order confirming the plan.7 Acute then appealed the confirmation order.8 The issue presented in that

appeal – as stated by Acute in its statement of the issues under Federal Rule of

2 Case No. 24-14430-SMG (Main Case), ECF No. 1. On their petitions, they both elected to have Subchapter V of Chapter 11 apply to their cases. 3 Main Case, ECF No. 193. 4 Main Case, ECF No. 257. 5 Acute, Inc. v. ECI Pharmaceuticals, LLC, Case No. 0:24-cv-61915-RAR (S.D. Fla.). ECI has moved to dismiss the appeal. The motion to dismiss has been fully briefed, but not yet decided. In light of the pending motion to dismiss, the District Court then extended Acute’s deadline to file its initial brief on the merits until ten days after it rules on that motion to dismiss. 6 Main Case, ECF No. 170. 7 Main Case, ECF No. 296. 8 Main Case, ECF No. 301. Bankruptcy Procedure 8009(a)(1)(A) – is whether this Court erred in confirming a plan that included certain allegedly inappropriate exculpation and injunction provisions.9 That appeal remains pending as well.10

The plan was premised on the sale of substantially all of the debtors’ assets being used to fund distributions to creditors. Because the sale has not yet closed, the plan has not been substantially consummated.11 Indeed, on January 17, 2025, the debtors served a notice of termination of the asset purchase agreement on Acute.12 Acute disputes the validity of the termination notice.13 Until either the debtors and Acute agree to resolve their differences or the appeals are decided, this case is at an

effective standstill. II. THIS ADVERSARY PROCEEDING. On February 26, 2025, Acute – together with creditors Genetic Networks LLC, and Dr. Raju’s Pharma Solutions, LLC – commenced this adversary proceeding under

9 Main Case, ECF No. 312. 10 Acute, Inc. v. ECI Pharmaceuticals, LLC, Case No. 0:24-cv-62112-RAR (S.D. Fla.). The appeal of the confirmation order has since been consolidated with the earlier appeal of the sale order, under Case No. 0:24-cv-61915-RAR (S.D. Fla.). ECI then moved to dismiss this appeal as well. That motion to dismiss has also been fully briefed, but not yet decided. The District Court then extended Acute’s deadline to file its initial brief on the merits of this appeal until fourteen days after it rules on that motion to dismiss. 11 As defined in 11 U.S.C. § 1101(2), “substantial consummation” means— (A) transfer of all or substantially all of the property proposed by the plan to be transferred; (B) assumption by the debtor or by the successor to the debtor under the plan of the business or of the management of all or substantially all of the property dealt with by the plan; and (C) commencement of distribution under the plan. 12 Main Case, ECF No. 325. 13 Main Case, ECF No. 327. 11 U.S.C. § 1144, seeking to revoke the confirmation order alleging that it was procured by fraud.14 Section 1144 provides in relevant part that: On request of a party in interest at any time before 180 days after the date of the entry of the order of confirmation, and after notice and a hearing, the court may revoke such order if and only if such order was procured by fraud.15 The defendants – debtors ECI and BioRamo, the ECI Liquidating Trust created by the plan, and Katie Goodman, the liquidating trustee under the plan – moved to dismiss the complaint under Federal Rules of Civil Procedure 12(b)(1) and (b)(6)16 and sought sanctions against Acute and its attorney for allegedly vexatious litigation practices.17 As grounds for dismissal, the defendants argue first that Acute’s pending appeal of the confirmation order divests this Court of jurisdiction to grant the relief requested.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

University of South Alabama v. American Tobacco Co.
168 F.3d 405 (Eleventh Circuit, 1999)
The United States v. Hudson and Goodwin
11 U.S. 32 (Supreme Court, 1812)
Griggs v. Provident Consumer Discount Co.
459 U.S. 56 (Supreme Court, 1982)
Kontrick v. Ryan
540 U.S. 443 (Supreme Court, 2004)
Marshall v. Marshall
547 U.S. 293 (Supreme Court, 2006)
In Re SCOPAC
624 F.3d 274 (Fifth Circuit, 2010)
Henderson v. Shinseki
131 S. Ct. 1197 (Supreme Court, 2011)
Stern v. Marshall
131 S. Ct. 2594 (Supreme Court, 2011)
United States v. John Frank Rodgers
101 F.3d 247 (Second Circuit, 1996)
In Re Winom Tool and Die, Inc.
173 B.R. 613 (E.D. Michigan, 1994)
In Re Calpine Corp.
389 B.R. 323 (S.D. New York, 2008)
Law v. Siegel
134 S. Ct. 1188 (Supreme Court, 2014)
Bullard v. Blue Hills Bank
575 U.S. 496 (Supreme Court, 2015)
Patchak v. Zinke
583 U.S. 244 (Supreme Court, 2018)
United States v. Rodriguez-Rosado
909 F.3d 472 (First Circuit, 2018)
Ritzen Group, Inc. v. Jackson Masonry, LLC
589 U.S. 35 (Supreme Court, 2020)
Elna Sefcovic v. TEP Rocky Mountain
953 F.3d 660 (Tenth Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
Acute Inc. v. ECI Pharmaceuticals LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/acute-inc-v-eci-pharmaceuticals-llc-flsb-2025.